Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero(Universitat Autònoma de Barcelona), Takayuki Yoshino(National Cancer Centre Japan), Allen Lee Cohn(Rocky Mountain Cancer Centers), Radka Obermannová(Masaryk Memorial Cancer Institute), G. Bodoky(Unified Szent István and Szent László Hospital), Rocio García‐Carbonero(Hospital Universitario Virgen del Rocío), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), David C. Portnoy(Campbell Clinic), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Axel Grothey(Mayo Clinic in Arizona), Jana Prausová(University Hospital in Motol), Pilar García‐Alfonso(Hospital General Universitario Gregorio Marañón), Kentaro Yamazaki(Shizuoka Cancer Center), Philip R. Clingan(Wollongong Hospital), Sara Lonardi(Istituto Oncologico Veneto), Tae Won Kim(University of Ulsan), Lorinda Simms(Eli Lilly (Canada)), Shao-Chun Chang(Eli Lilly (United States)), Federico Nasroulah(Eli Lilly (United States))
Cited by 953
Abstract
Related Papers
No related papers found
Powered by citation graph analysis